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In 1999 the membership of the International Life Sciences Institute
(ILSI) Health and Environmental Sciences Institute (HESI) formed a
multisector consortium to address challenges associated with the inte-
gration of genomics data into risk assessment (Pennie et al. 2004).
Following its formation, the HESI Committee on the Application of
Genomics to Mechanism-Based Risk Assessment identified several
key hurdles. These included a lack of publicly available toxico-
genomics databases, a lack of validation of available technologies,
questions concerning the comparability of different technical plat-
forms and how transcription products relate to toxicity, and uncer-
tain regulatory applications. 
In 2004 we have seen considerable progress in many of the
areas mentioned above, particularly in our technical ability to exe-
cute microarrays and to analyze and interpret the resultant data.
The experimental program of the HESI Genomics Committee
clearly demonstrated that it is possible to replicate data on biologic
pathways across laboratories and technical platforms (Kramer et al.
2004; Ulrich et al. 2004). The committee’s work also revealed the
need to interpret modulations in gene expression on microarrays in
the context of a broader biologic data set (e.g., clinical chemistry,
histopathology). Additionally, within the United States, the recent
release of draft regulatory guidance from the U.S. Food and Drug
Administration (FDA 2003) on the use of pharmacogenomics data
in risk assessment and the release of a white paper from the U.S.
Environmental Protection Agency (U.S. EPA 2004) on potential
regulatory applications of genomics data have further focused
potential applications. However, the routine application of
genomics to preclinical risk assessment has not yet been accepted
universally. Why?
The efforts of the HESI Committee on Genomics regarding
experimental collaboration and toxicogenomics database develop-
ment (Mattes et al. 2004) suggest that some of the greatest out-
standing challenges relate to effective communication across key
user groups. It is critical that regulated industries share with the
regulatory community the focus of their current approaches to the
use of genomics. For example, are microarray data used primarily
for early screening or for researching mechanisms of toxicity and
and under what circumstances? Additionally, open information
exchange regarding typical means of data analysis and presentation
is needed. This exchange, which has been initiated via several
multisector forums including HESI, will help ensure that a com-
mon understanding of the technology’s practical strengths and lim-
itations is reached and allow genomics to be applied more
effectively to safety assessment. Discussions concerning the inter-
pretation of patterns of change in gene expression in relation to
other biologic end points will provide critical context for determin-
ing the suitability of a data set for risk evaluation. Consensus as to
when changes in gene expression via microarray represent definitive
biomarkers of effect is also needed. Until
these conditions are clarified, the utility of
genomics for classifying effects of concern
will remain debatable. 
The risk assessment community is
also striving both to harness the collective
power of publicly available data sets and to
facilitate exchange of single data sets for safety evaluation. As such,
numerous formats for the capture and exchange of microarray and
toxicology data have become available and/or are under develop-
ment (Mattes et al. 2004). Diversity of approach is not in itself
problematic and clearly has its benefits. However, the development
of flexible and comprehensible data exchange platforms that meet
the needs of multiple user groups is essential for routine exchange of
toxicogenomics data. 
The HESI Committee on Genomics looks forward to an
ongoing role as a multi-stakeholder consortium committed to
facilitating discussion on the scientifically sound use of genomics
for risk assessment. 
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Early identification of toxicologic side effects of a drug candidate is
critical to an efficient drug discovery and development process.
Toxicogenomics, the marriage of data-rich genomics approaches
with traditional toxicologic end point evaluation combined with
increasingly powerful in silico modeling approaches, promises to
accelerate this process. The advent of parallel experimental plat-
forms, for example, DNA microarrays, has enabled us to gain
insight into complex biologic responses to drugs. The challenge is
to analyze and correctly interpret these large data sets. Currently,
no common standards exist for such data even though attempts are
being made to streamline and standardize the presentation of the
information. These efforts include ArrayExpress infrastructure for
microarray data (http://www.ebi.ac.uk/arrayexpress), Minimum
Information About a Microarray Experiment (http://www.mged.
org/Workgroups/MIAME/miame.html), and MicroArray Gene
Expression (MAGE) markup language (http://www.mged.org;
http://www.omg.org/technology/documents/formal/gene_
expression.htm). 
The creation of vast amounts of genomics and toxicogenomics
data has sparked the development of novel systems to handle this
type of information. Ultimately, the success of a toxicogenomics
approach in drug development depends on our ability to interpret
the data in relation to existing information (e.g., screening of a
drug-induced gene expression fingerprint against a database con-
taining drug-related gene expression toxicity profiles). It is critical
that interdisciplinary information (chemistry, biochemistry,
genetic, genomics, clinical) be integrated into the same data ware-
house. Incorporating toxicogenomics data into this approach,
which is often referred to as systems biology, will help us under-
stand in much more depth how cells maintain homeostasis and
how organisms respond to drug exposure at the molecular level.
The mission of the U.S. Food and Drug Adminstration (FDA)
states that the agency “. . . is responsible for advancing the public
health by helping to speed innovations that make medicines and
foods more effective, safer, and more affordable. . . .” (FDA 2004).
Former agency commissioner Mark McClellan stated that “the FDA
priority is facilitating the use of pharmacogenetics-driven treat-
ments” (Salerno and Lesko 2004). The FDA has recently issued a
draft, “Guidance for Industry: Pharmacogenomic Data
Submissions” (FDA 2003), and has held workshops to discuss issues
related to pharmacogenomics data submissions (Salerno and Lesko
2004a, 2004b; Leighton et al. 2004; Ruaño et al. 2004; Trepicchio
et al. 2004). This guidance is being revised on the basis of public
comments, and a final guidance should be issued later this year.
Many principles found in this guidance apply to toxicogenomics
studies. In particular, the identification, evaluation, and validation of
biomarkers are critical components of every pharmacogenomics, as
well as toxicogenomics, study of cases in regulatory decision making.
The guidance is general and includes examples of genetic and
genomic biomarkers: a CYP2D6 (cytochrome P450 2D6) mutation
versus an increase in HER2 (human epidermal growth factor recep-
tor 2) expression can be viewed as genetic and genomic biomarkers,
respectively. However, it is anticipated that future data submissions
will contain many more complex gene expression profiles and large-
scale single nucleotide polymorphism maps (e.g., from whole
genome scans), which will present new challenges to define the ana-
lytical and clinical validity of such new and highly complex bio-
marker sets. The guidance represents the FDA’s current view on
pharmacogenomics and what the agency believes are the scientific
grounds for evaluating such information as it relates to voluntary
versus required submission of data.
What are the next steps? Regulators have been criticized for the
lack of guidance in the new era of genomics-based drug develop-
ment. In addition to the guidance on pharmacogenomics data sub-
missions (FDA 2003), the FDA is embarking on a new guidance
initiative for the co-development of pharmacogenomics-based drugs
and biologic products and the diagnostic tests necessary for therapeu-
tic decision making. Recently, the FDA and the Drug Information
Association (DIA) sponsored a pharmacogenomics workshop
(FDA/DIA 2004). The purpose of the workshop was to identify
issues in the development of pharmacogenomics-based combination
products. We hope to see the base of pharmacogenomics knowledge
grow and expand, and we look forward to the use of this information
in the drug discovery and regulatory evaluation processes. We expect
that not only the novel scientific but also the newly created regula-
tory tools such as voluntary submissions of genomics data will pro-
vide the means by which genomics-based research can excel in
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The two editorials in this issue of EHP address the application
of toxicogenomics data in the risk assessment and regulatory
processes. Also addressing these issues is the National Research
Council/National Academy of Sciences Committee on
Emerging Issues and Data on Environmental Contaminants.
(http://dels.nas.edu/emergingissues/index.asp). This commit-
tee, formed at the request of the National Institute of
Environmental Health Sciences (NIEHS), provides a pub-
lic forum for discussing emerging issues in environmental
toxicology. 
The committee comprises experts from academia, indus-
try, and public interest groups whose specialties include tox-
icology, toxicogenomics, genetics, bioinformatics, risk
assessment, medical ethics, epidemiology, communications,
public health. In addition, a U.S. federal government liaison
group has been created to work with the committee with
representatives from the NIEHS, the Centers for Disease
Control and Prevention, the Environmental Protection
Agency, the Food and Drug Administration, the
Department of Agriculture, the Department of Energy, the
Occupational Safety and Health Administration, the
Department of Defense, and the Department of
Transportation. 
A subcommittee is being formed to write a “Consensus
Report on the Applications of Toxicogenomic
Technologies to Predictive Toxicology.” This report will
highlight how the study of gene and protein activities and
other biological processes can improve the characterization
of toxic substances and their potential risks. Ultimately,
this report should show how major new or anticipated uses
of these technologies could improve the protection of pub-
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